Indivior Pharmaceuticals, Inc. — Income Charts
9 quarters of history · ending 2026-03-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+19.2% +$51M
$317M
Cost of Revenue↓-9.1% -$4M
$40M
Gross Profit↑+25.3% +$56M
$277M
R&D↓-27.3% -$6M
$16M
SG&A↓-6.8% -$9M
$124M
D&A↓-33.3% -$1M
$2M
Operating Income↑+107.6% +$71M
$137M
EBITDA↑+101.4% +$70M
$139M
Interest Expense↓-41.7% -$5M
$7M
Interest Income↓-25.0% -$1M
$3M
Other Income/Expense↓-1900.0% -$19M
$-18M
Pretax Income↑+94.9% +$56M
$115M
Tax Provision↑+136.4% +$15M
$26M
Net Income↑+89.4% +$42M
$89M
Gross Margin↑+4.3pts
87.4%
Operating Margin↑+18.4pts
43.2%
Net Margin↑+10.4pts
28.1%
Effective Tax Rate↑+4.0pts
22.6%
Deferred Tax Assets↑+6.1% +$17M
$296M
ETR (Continuing Operations)↓-52.8pts
12.2%
ETR Federal Statutory↑+0.0pts
25.0%
ETR State + Local (pp)
0.0%
ETR Foreign Differential (pp)
8.8%
Revenue YoY Variation↑+25.5pts
19.2%
Income YoY Variation↑+119.6pts
107.6%
Revenue QoQ Variation↓-0.4pts
-11.5%
Income QoQ Variation↑+25.7pts
69.1%